FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387472649> ?p ?o ?g. }

• W4387472649 abstract "The eighth-leading cause of cancer-related mortality and the seventh-most prevalent malignancy in women globally is ovarian cancer (OV). However, 5-year survival expectancy after conventional treatment is not good. Therefore, there is an urgent need for novel signatures to guide the designation of therapeutic schemes for OV patients.We used univariate Cox analysis to screen hormone secretion regulation axis-related microRNAs (miRNAs), least absolute shrinkage and selection operator analysis to select candidate miRNAs and multivariate Cox analysis to build the risk model. To evaluate possible route and functional differences, enrichment analysis using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed on the differentially expressed genes (DEGs) across various risk groups. We compared Tumor Immune Dysfunction and Exclusion (TIDE) scores across risk categories by analyzing immune cell infiltration, immune checkpoint gene expression, immunological function and TIDE scores. In the end, we determined the half maximal inhibitory concentration (IC50 ) of chemotherapy and targeted medicines for individual patients. Cell assays were determined to test the migration of the miRNA-target genes and western blotting was used to test the correlation of the miRNA-target genes and the pathways.We finally identified hormone secretion regulation axis-related 13 microRNAs to build a risk model. The validation of observed and anticipated values revealed a fair level of agreement. To evaluate the molecular pathways between various groups in accordance with the GO and KEGG analyses, we then discovered 173 DEGs between distinct risk groups. The risk score was shown to be inversely related to the number of immune cells, including myeloid dendritic, granulocytes, M1 and M2 macrophages, B cells, t-lymphocytes, and CD4+ and CD8+ cells, suggesting that immune cells are more frequent in the low-risk group. Immune cell infiltration investigation yielded these results. Finally, we recognized 11 chemotherapeutic drugs and 30 novels targeted drugs on the basis of IC50 between the different risk groups. GJB5 was determined to be the mir-219 target gene and was identified as promoting the cell cycle process. In addition, hormone secretion regulation axis related miRNAs were reported to affects the heterogeneity of endocrine microenvironment and anti-tumor immune pattern.In conclusion, a 13-miRNA prognostic model was constructed to know the immune status, prognosis, immunotherapeutic response and anti-tumor drug sensitivity for OV, which provides theoretical guidance for the effective and individualized treatment of OV patients." @default.
• W4387472649 created "2023-10-11" @default.
• W4387472649 creator A5005215725 @default.
• W4387472649 creator A5022366110 @default.
• W4387472649 creator A5030850216 @default.
• W4387472649 creator A5033252398 @default.
• W4387472649 creator A5041181413 @default.
• W4387472649 creator A5049537151 @default.
• W4387472649 creator A5072315367 @default.
• W4387472649 creator A5075851722 @default.
• W4387472649 creator A5076137654 @default.
• W4387472649 date "2023-10-09" @default.
• W4387472649 modified "2023-10-12" @default.
• W4387472649 title "Ovarian carcinoma immune‐related microRNA affects the heterogeneity of the endocrine microenvironment and anti‐tumor immune pattern" @default.
• W4387472649 cites W1985987855 @default.
• W4387472649 cites W2006247279 @default.
• W4387472649 cites W2075294566 @default.
• W4387472649 cites W2114586150 @default.
• W4387472649 cites W2144922697 @default.
• W4387472649 cites W2146512944 @default.
• W4387472649 cites W2472674516 @default.
• W4387472649 cites W2536204818 @default.
• W4387472649 cites W2563045617 @default.
• W4387472649 cites W2600132724 @default.
• W4387472649 cites W2791279457 @default.
• W4387472649 cites W2896019639 @default.
• W4387472649 cites W2896872272 @default.
• W4387472649 cites W2898813162 @default.
• W4387472649 cites W2909800464 @default.
• W4387472649 cites W2922503148 @default.
• W4387472649 cites W2950407919 @default.
• W4387472649 cites W2954320913 @default.
• W4387472649 cites W2970295470 @default.
• W4387472649 cites W2994977341 @default.
• W4387472649 cites W2995638049 @default.
• W4387472649 cites W2996212786 @default.
• W4387472649 cites W2998766404 @default.
• W4387472649 cites W3034231292 @default.
• W4387472649 cites W3044903507 @default.
• W4387472649 cites W3092122627 @default.
• W4387472649 cites W3093151636 @default.
• W4387472649 cites W3096383358 @default.
• W4387472649 cites W3103608461 @default.
• W4387472649 cites W3119005666 @default.
• W4387472649 cites W3128646645 @default.
• W4387472649 cites W3158158224 @default.
• W4387472649 cites W3175752499 @default.
• W4387472649 cites W3194220728 @default.
• W4387472649 cites W4210359607 @default.
• W4387472649 cites W4280519874 @default.
• W4387472649 cites W4283719145 @default.
• W4387472649 cites W4294541781 @default.
• W4387472649 cites W4295226745 @default.
• W4387472649 doi "https://doi.org/10.1002/jgm.3602" @default.
• W4387472649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37813677" @default.
• W4387472649 hasPublicationYear "2023" @default.
• W4387472649 type Work @default.
• W4387472649 citedByCount "0" @default.
• W4387472649 crossrefType "journal-article" @default.
• W4387472649 hasAuthorship W4387472649A5005215725 @default.
• W4387472649 hasAuthorship W4387472649A5022366110 @default.
• W4387472649 hasAuthorship W4387472649A5030850216 @default.
• W4387472649 hasAuthorship W4387472649A5033252398 @default.
• W4387472649 hasAuthorship W4387472649A5041181413 @default.
• W4387472649 hasAuthorship W4387472649A5049537151 @default.
• W4387472649 hasAuthorship W4387472649A5072315367 @default.
• W4387472649 hasAuthorship W4387472649A5075851722 @default.
• W4387472649 hasAuthorship W4387472649A5076137654 @default.
• W4387472649 hasConcept C104317684 @default.
• W4387472649 hasConcept C126322002 @default.
• W4387472649 hasConcept C143998085 @default.
• W4387472649 hasConcept C145059251 @default.
• W4387472649 hasConcept C150194340 @default.
• W4387472649 hasConcept C152724338 @default.
• W4387472649 hasConcept C162317418 @default.
• W4387472649 hasConcept C203014093 @default.
• W4387472649 hasConcept C2776107976 @default.
• W4387472649 hasConcept C2779399171 @default.
• W4387472649 hasConcept C502942594 @default.
• W4387472649 hasConcept C54355233 @default.
• W4387472649 hasConcept C60644358 @default.
• W4387472649 hasConcept C70721500 @default.
• W4387472649 hasConcept C71924100 @default.
• W4387472649 hasConcept C86803240 @default.
• W4387472649 hasConcept C8891405 @default.
• W4387472649 hasConceptScore W4387472649C104317684 @default.
• W4387472649 hasConceptScore W4387472649C126322002 @default.
• W4387472649 hasConceptScore W4387472649C143998085 @default.
• W4387472649 hasConceptScore W4387472649C145059251 @default.
• W4387472649 hasConceptScore W4387472649C150194340 @default.
• W4387472649 hasConceptScore W4387472649C152724338 @default.
• W4387472649 hasConceptScore W4387472649C162317418 @default.
• W4387472649 hasConceptScore W4387472649C203014093 @default.
• W4387472649 hasConceptScore W4387472649C2776107976 @default.
• W4387472649 hasConceptScore W4387472649C2779399171 @default.
• W4387472649 hasConceptScore W4387472649C502942594 @default.
• W4387472649 hasConceptScore W4387472649C54355233 @default.
• W4387472649 hasConceptScore W4387472649C60644358 @default.
• W4387472649 hasConceptScore W4387472649C70721500 @default.
• W4387472649 hasConceptScore W4387472649C71924100 @default.

• next